First Pacific Financial Buys 4,087 Shares of Johnson & Johnson $JNJ

First Pacific Financial lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 18.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 26,468 shares of the company’s stock after buying an additional 4,087 shares during the quarter. Johnson & Johnson comprises 0.7% of First Pacific Financial’s portfolio, making the stock its 25th largest position. First Pacific Financial’s holdings in Johnson & Johnson were worth $7,007,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of JNJ. Cliftonlarsonallen Wealth Advisors LLC lifted its stake in shares of Johnson & Johnson by 23.5% in the 3rd quarter. Cliftonlarsonallen Wealth Advisors LLC now owns 39,674 shares of the company’s stock valued at $10,503,000 after purchasing an additional 7,547 shares during the period. Fortitude Family Office LLC boosted its position in shares of Johnson & Johnson by 19.2% during the third quarter. Fortitude Family Office LLC now owns 2,198 shares of the company’s stock valued at $582,000 after purchasing an additional 354 shares in the last quarter. Harbor Group Inc. purchased a new stake in Johnson & Johnson in the third quarter worth $356,000. Weil Company Inc. grew its stake in Johnson & Johnson by 9.4% in the third quarter. Weil Company Inc. now owns 10,593 shares of the company’s stock worth $2,804,000 after purchasing an additional 913 shares during the period. Finally, Western Financial Corp CA raised its holdings in Johnson & Johnson by 3.4% in the third quarter. Western Financial Corp CA now owns 19,451 shares of the company’s stock worth $5,150,000 after purchasing an additional 632 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $253.49 on Thursday. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44. The stock has a market cap of $610.89 billion, a P/E ratio of 38.41, a P/E/G ratio of 2.54 and a beta of 0.21. The business’s 50 day moving average price is $265.80 and its 200-day moving average price is $249.47. Johnson & Johnson has a 52 week low of $184.66 and a 52 week high of $281.07.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, beating analysts’ consensus estimates of $2.53 by $0.06. The company had revenue of $25.40 billion during the quarter, compared to analyst estimates of $25.38 billion. Johnson & Johnson had a return on equity of 31.54% and a net margin of 16.20%. The firm’s revenue for the quarter was up 5.9% on a year-over-year basis. During the same quarter last year, the company earned $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Equities research analysts anticipate that Johnson & Johnson will post 11.10 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be paid a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio is currently 62.11%.

Wall Street Analyst Weigh In

JNJ has been the subject of several recent research reports. Freedom Capital raised Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 16th. HSBC upped their target price on shares of Johnson & Johnson from $290.00 to $320.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. Royal Bank Of Canada reduced their target price on shares of Johnson & Johnson from $290.00 to $280.00 and set an “outperform” rating on the stock in a research report on Wednesday. Wall Street Zen lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Finally, TD Cowen lifted their price target on shares of Johnson & Johnson from $250.00 to $300.00 and gave the company a “buy” rating in a research report on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $273.61.

Insider Buying and Selling

In other news, EVP Vanessa Broadhurst sold 23,054 shares of the firm’s stock in a transaction on Monday, July 20th. The stock was sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the completion of the transaction, the executive vice president directly owned 23,003 shares in the company, valued at $5,779,963.81. This trade represents a 50.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Timothy Schmid sold 33,597 shares of Johnson & Johnson stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the transaction, the executive vice president directly owned 25,447 shares of the company’s stock, valued at approximately $6,991,308.78. This represents a 56.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 87,569 shares of company stock valued at $23,064,544. Insiders own 0.16% of the company’s stock.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: JNJ exceeded third-quarter adjusted earnings expectations, reporting EPS of $2.59 versus a $2.53 consensus, while revenue rose 5.9% year over year to $25.4 billion. Innovative Medicine was the primary growth engine, with reported 7.9% growth and strong demand for newer products. Johnson & Johnson reports Q3 2026 results and raises 2026 guidance
• Positive Sentiment: The company raised its 2026 outlook to $101.0 billion-$101.4 billion in revenue and $11.05-$11.15 in adjusted EPS. The improved forecast provides support for the stock despite the quarter’s mixed details. JNJ Q3 earnings call highlights
• Positive Sentiment: JNJ declared a quarterly dividend of $1.34 per share, equivalent to $5.36 annually and approximately a 2.2% yield, reinforcing its appeal to income-focused investors. Johnson & Johnson announces quarterly dividend

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.